Compare KRG & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRG | TGTX |
|---|---|---|
| Founded | 1971 | 1993 |
| Country | United States | United States |
| Employees | 228 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.9B |
| IPO Year | 2004 | 2008 |
| Metric | KRG | TGTX |
|---|---|---|
| Price | $24.15 | $31.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | $25.82 | ★ $49.80 |
| AVG Volume (30 Days) | 1.5M | ★ 2.0M |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | ★ 4.78% | N/A |
| EPS Growth | ★ 6750.00 | 1746.67 |
| EPS | 1.37 | ★ 2.77 |
| Revenue | ★ $844,365,000.00 | $2,785,000.00 |
| Revenue This Year | N/A | $49.30 |
| Revenue Next Year | N/A | $24.55 |
| P/E Ratio | $17.69 | ★ $11.53 |
| Revenue Growth | ★ 0.30 | N/A |
| 52 Week Low | $18.52 | $25.37 |
| 52 Week High | $26.38 | $46.48 |
| Indicator | KRG | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 34.03 | 59.70 |
| Support Level | $21.87 | $29.81 |
| Resistance Level | $24.50 | $32.96 |
| Average True Range (ATR) | 0.47 | 1.40 |
| MACD | -0.21 | 0.31 |
| Stochastic Oscillator | 1.66 | 87.22 |
Kite Realty Group Trust specializing in high-quality, open-air shopping centers and mixed-use assets. Concentrated in the Sun Belt and strategic gateway markets, the company focuses on grocery-anchored, necessity-based retail. The company generates the majority of its revenue from contractual rents and reimbursement payments received from tenants.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.